



FigureS1



FigureS1 SAM promotes the growth and drug resistance of CRC cells. (a) The CCK-8 assay detects the cytotoxicity of the FOLFOX chemotherapy regimen on MC38 cells. (b) The CCK-8 assay evaluates the impact of SAM on the proliferation capability of MC38 cells. (c) The CCK-8 assay assesses the cell viability of MC38 cells when treated with SAM in combination with FOLFOX. (d) The EdU labeling assay assesses the proliferation capability of MC38 cells when treated with SAM in combination

with FOLFOX. The results are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.001$. Statistical significance was determined by one-way or two-way ANOVA.

FigureS2



FigureS2 Silencing METTL3 reduced the activation of the JAK2-STAT3 signaling pathway. (a) Knocking down METTL3 in MC38 and HCT116 cells resulted in a decrease in the protein expression of the JAK2-STAT3 signaling pathway. (b) After silencing METTL3, the proliferation capacity of MC38 and HCT116 cells decreased. The results are presented as mean \pm SEM. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.005$, **** $p < 0.001$. Statistical significance was determined by one-way or two-way ANOVA.